Distinguished in Hepatitis C

Dr. Lisa Forman

Hepatology
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical Campus, 
Aurora, CO 
 (873.9 mi)
Offers Telehealth
Distinguished in Hepatitis C
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical Campus, 
Aurora, CO 
 (873.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Lisa Forman is a Hepatologist in Aurora, Colorado. Dr. Forman and is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Cholangitis, Sclerosing Cholangitis, Primary Biliary Cholangitis, Liver Transplant, and Endoscopy.

Her clinical research consists of co-authoring 28 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Hepatitis C.

Specialties
Hepatology
Licenses
Internal Medicine in CO
Hospital Affiliations
Uchealth Highlands Ranch Hospital
Poudre Valley Hospital
University Of Colorado Hospital Authority
Uchealth Greeley Hospital
Medical Center Of The Rockies
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  UnitedHealthcare
  •  Humana

Locations

UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical Campus, Aurora, CO 80045

Additional Areas of Focus

Dr. Forman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

28 Total Publications

Marked variation in disease acuity and outcomes on the liver transplant waiting list by sociodemographic characteristics.
Marked variation in disease acuity and outcomes on the liver transplant waiting list by sociodemographic characteristics.
Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Published: June 26, 2024
Similar Doctors
Distinguished in Hepatitis C
Dr. John P. Norvell
Hepatology
Distinguished in Hepatitis C
Dr. John P. Norvell
Hepatology

University Physicians Incorporated

1635 Aurora Ct, 
Aurora, CO 
 (0.2 mi)
720-848-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Norvell is a Hepatologist in Aurora, Colorado. Dr. Norvell and is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Liver Transplant, and Endoscopy.

Distinguished in Hepatitis C
Dr. Whitney Jackson
Hepatology
Distinguished in Hepatitis C
Dr. Whitney Jackson
Hepatology

University Physicians Incorporated

13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
 (0.4 mi)
720-777-1234
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Whitney Jackson is a Hepatologist in Aurora, Colorado. Dr. Jackson has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis, Hepatitis C, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy.

Distinguished in Hepatitis C
Dr. Todd Sheer
Hepatology
Distinguished in Hepatitis C
Dr. Todd Sheer
Hepatology

Catholic Health Initiatives Colorado

41 State Hwy 67, 
Woodland Park, CO 
 (53.1 mi)
719-776-4780
Languages Spoken:
English
See accepted insurances

Todd Sheer is a Hepatologist in Woodland Park, Colorado. Dr. Sheer and is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Endoscopy, and Colonoscopy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile